$AVR

Anteris Technologies Global Corp. (AVR): Entry into a Material Definitive Agreement

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 22, 2026, Anteris Aus Operations Pty Ltd (“AAOPL”), a wholly owned subsidiary of Anteris Technologies Global Corp., and Harvey Industries Group Pty Ltd (“Harvey”, together with AAOPL, the “Parties”), entered into

Original reporting
Published Sep 23, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 11:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

The amendment extends the agreement term but does not change other material terms, suggesting limited immediate financial impact.

02

Market read

Primary disclosure of a contract amendment with modest relevance for traders.

03

What to watch

Potential downstream effects on partner Harvey Industries are not detailed.

Relevance 6/10Novelty 4/10Timing: filed Sep 23 2026

Background

SEC Form 8‑K filing discloses a material amendment to a supply agreement for Anteris Technologies.

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

Anteris Technologies Global Corp. filed an 8‑K reporting an amendment to its supply and quality agreement, extending its term.

Expected impact

Limited short‑term price movement expected.

Evidence & confidence

Material agreement amendment disclosed for the first time, but no monetary terms or scale disclosed.

Market effects

Minor impact on the medical device supply chain sector.

No significant regional effect.

Limited relevance to global markets.

Counterpoint

The amendment could signal longer‑term stability, offering a modest upside.

Key entities

  • Anteris Technologies Global Corp.

    Issuer of the 8‑K filing.

  • Harvey Industries Group Pty Ltd

    Counterparty to the supply agreement.

Related articles

$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

$AVRLow

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe